Enasidenib – an oral, targeted, small‐molecule inhibitor of mutant IDH2 – has been evaluated as a single agent in a Phase 1 study in mutant IDH2 R/R AML patients and subsequently approved by the FDA [60]. The gene discussed is IDH2; the disease is acute myeloid leukemia.